|
|
Article: BioMarin Announces Positive Results from Phase 3 Diet Study of Phenoptin and Study Show Genzyme's Cerezyme May Be Effective.
- Article from:
- M2 Presswire
- Article date:
- January 17, 2007
CopyrightCOPYRIGHT 2007 M2 Communications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-17 January 2007-U.S. Equity News: BioMarin Announces Positive Results from Phase 3 Diet Study of Phenoptin and Study Show Genzyme's Cerezyme May Be Effective(C)1994-2007 M2 COMMUNICATIONS LTD
RDATE:17012007
City of Industry, CA - Biotechnology industry alert provided by U.S. Equity News. BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) recently announced positive results from the Phase 3 diet study of Phenoptin(TM) (sapropterin dihydrochloride), in combination with diet, in 4-12 year old patients. Phenoptin is an investigational oral small molecule, being developed in partnership with Merck Serono, for the treatment of patients with ...
Related newspaper, magazine, and journal articles:
|
|
Article: Equity Solutions Signs Affiliate Agreement With ...
M2 Presswire;
October 13, 2006 ;
689 words
... ... October 2006-U.S. Equity News: Equity Solutions Signs Affiliate Agreement ... locations worldwide. About Equity Solutions, Inc. Equity Solutions, Inc. (www.EquityIRSolutions ... acquisitions. About U.S. Equity News U.S. Equity News provides ...
|
|